Iderapharma.com
Iderapharma is ranked 738,303 in the United Kingdom. 'Idera Pharmaceuticals: Toll-like Receptor (TLR) Drug Discovery.'
738,303Rank in United Kingdom
11,118,709Worldwide Rank
Monthly pages viewed | 938 | |
Monthly visits | 938 | |
Value per visitor | £0.11 | |
Estimated worth | £671.28 | |
External links | 130 | |
Number of pages | 750 |
Last Updated: 05/04/2018 . Estimated data, read disclaimer.
Visitors
Traffic History 90 Day Average | ||
Worldwide Rank | 9,343,453 | 577,619 |
---|---|---|
Daily Visitors | 21 | +40% |
Daily Visitors Rank | 8,087,790 | -2,669,648 |
Daily Pageviews | 0 | -67.86% |
Daily Pageviews Rank | 11,826,764 | 5,373,272 |
Pageviews Per User | 1.00 | -76.96% |
Content
www.Iderapharma.com
Topics: Discovery, Collaborations, Partnering Opportunities, and Pipeline.
Age: The domain is 12 years and 10 months old.
- Popular pages
- iderapharma.com Safety and Pharmacodynamics of IMO-3100, a Novel Toll-like ..
- ir.iderapharma.com News Release - Idera Pharmaceuticals
- iderapharma.com Contact Infromation and Directions - Idera Pharmaceuticals
- iderapharma.com TLR Antagonists - Research - Idera Pharmaceuticals
On average 1 page are viewed each, by the estimated 23 daily visitors.
Links- Links out
- ncbi.nlm.nih.gov Modifications incorporated in CpG motifs of oligo... [J Med Chem
- ncbi.nlm.nih.gov Inhibition of Rous sarcoma viral RNA translation by a specific
- phx.corporate-ir.net 2011 News - Idera Pharmaceuticals
Server Location | |
Xo Communications Virginia United States 37.300275, -93.339844 |
It has 4 nameservers, including dns2.iderapharma.com, dns.iderapharma.com, and nse.algx.net. Its local IP address is 209.48.129.8. It is hosted by Xo Communications Virginia, using Microsoft-IIS/6 web server.
IP: 209.48.129.8
Web Server: Microsoft-IIS/6
Encoding: utf-8
Server Setup | |
Content-Length: | 5993 |
---|---|
Content-Type: | text/html |
Content-Location: | /index.html |
Last-Modified: | -- |
Accept-Ranges: | bytes |
ETag: | "5aeab9d2491fce1:f3f" |
Server: | Microsoft-IIS/6.0 |
Date: | -- |